- 1 Heterologous immunisation with vector vaccine as prime followed by mRNA vaccine as boost leads
- 2 to humoral immune response against SARS-CoV-2, which is comparable to that according to a
- 3 homologous mRNA vaccination scheme
- 4 Ruben Rose ^{1,†}, Franziska Neumann ^{2, †}, Olaf Grobe ², Thomas Lorentz ², Helmut Fickenscher ¹,
- 5 Andi Krumbholz 1, 2,*
- 6 1 Institut für Infektionsmedizin, Christian-Albrechts-Universität zu Kiel und Universitätsklinikum
- 7 Schleswig Holstein, Campus Kiel, Brunswiker Straße 4, D-24105 Kiel, Germany
- 8 2 Labor Dr. Krause und Kollegen MVZ GmbH, Steenbeker Weg 23, D-24106 Kiel, Germany
- 9 * Correspondence: krumbholz@infmed.uni-kiel.de; Tel.: +49-431-22010131
- 10 † These first authors contributed equally

11 Abstract

- 12 Background: The humoral immune response after primary immunisation with a SARS-CoV-2 vector
- 13 vaccine (AstraZeneca AZD1222, ChAdOx1 nCoV-19, Vaxzevria) followed by an mRNA vaccine boost
- 14 (BioNTech, BNT162b2; Moderna, m-1273) was examined and compared with the antibody response
- 15 after homologous vaccination schemes (AZD1222/AZD1222 or BNT162b2/BNT162b2).
- 16 Methods: Sera from 59 vaccinees were tested for SARS-CoV-2 immunoglobulin G (IgG) and virus-
- 17 neutralising antibodies (VNA) with four IgG assays, a surrogate neutralisation test (sVNT) and a Vero
- 18 cell-based neutralisation test (cVNT) before and after heterologous (n=31 and 42) or homologous
- 19 booster vaccination (AZD1222/AZD1222, n=8/9; BNT162b2/BNT162b2, n=8/8). The strength of IgG
- 20 binding to separate SARS-CoV-2 antigens was measured as avidity.
- 21 **Results:** After the first vaccination, prevalence of IgGs antibodies directed against (trimeric) SARS-CoV-
- 22 2 spike (S)- protein and its receptor-binding domain (RBD) varied from 55-95 % (AZD1222) to 100%
- 23 (BNT162b2), depending on the vaccine used and the SARS-CoV-2 antigen used. The booster vaccination
- 24 resulted in 100 percent seroconversion and appearance of highly avid IgG as well as VNA against a
- 25 SARS-CoV-2 variant of concern (alpha; B.1.1.7) used as antigen in the cVNT. The results of the sVNT
- 26 basically agree with those of our in-house cVNT, but the sVNT seems to overestimate non- and weakly
- 27 virus-neutralizing titres. The mean IgG and VNA titres were higher after heterologous vaccination
- 28 compared to the homologous AZD1222 scheme.
- 29 **Conclusions:** The heterologous SARS-CoV-2 vaccination leads to a strong antibody response with anti-
- 30 SARS-CoV-2 IgG and VNA titres at a level comparable to that of a homologous BNT162b2 vaccination
- 31 scheme. Irrespectively of the chosen immunisation regime, highly avid IgG antibodies can be detected
- 32 just two weeks after the second vaccine dose indicating the development of a robust humoral
- 33 immunity.

35

34 **Keywords:** COVID-19; vaccination schemes; immunoglobulin G; maturity process; virus-neutralisation NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Background

- 37 Since spring 2020 the pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-
- 38 CoV-2) [1] is ongoing and represents a global challenge. The availability of safe and effective
- 39 vaccinations are seen as one of the most important pillars in containing the pandemic [2, 3]. Within a
- 40 few months, the intensive research activities led to the development of several highly effective SARS-
- 41 CoV-2 vaccines [4, 5, 3]. In addition to the induction of cellular immunity, their administration should
- 42 stimulate the formation of virus-neutralising antibodies (VNA) that bind to epitopes of the viral spike
- 43 (S) protein and its receptor binding domain (RBD) and, thus, prevent the cells from being infected [6,
- 44 7, 3].
- 45 Four SARS-CoV-2 vaccines have received conditional approval in the European Union. These vaccines
- are based on two different technologies [8]. For the messenger ribonucleic acid (mRNA) vaccines from
- 47 Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273), the genetic information for the S-protein
- 48 was genetically optimized and the mRNA was packaged in liposomes. After inoculation, the muscle
- 49 cells directly expressed this stable and highly immunogenic viral surface protein [2, 6]. In vector
- 50 vaccines, replication-deficient human (Ad26.COV2; Janssen) or chimpanzee adenoviruses (ChAdOx1
- 51 nCoV-19/AZD1222, Vaxzevria; AstraZeneca, hereinafter referred to as AZD1222) are used to introduce
- 52 the genetic information of the SARS-CoV-2 S-protein into the cells, followed by transcription of
- 53 deoxyribonucleic acid into mRNA and expression of the S-protein [2, 6].
- 54 Due to the widespread use of these vaccines, rare and sometimes unexpected side effects have been
- 55 reported. Particularly noteworthy are cases of immune thrombotic thrombocytopenia, which
- 56 predominantly occurred in women under 50 years of age within one month after the initial vaccination
- 57 with AZD1222 [5]. Many of these patients developed cerebral sinus venous thrombosis or splanchnic
- 58 vein thrombosis and presented antibodies to platelet factor 4 but without previous exposure to
- 59 heparin [5]. Due to this rare but serious side effect, AZD1222 is no longer unreservedly recommended
- 60 by the Standing Vaccination Commission (STIKO) of the Robert Koch Institute for individuals under 60
- 61 years of age. The STIKO suggests that a vaccination with AZD1222 that has already started should be
- 62 completed with an mRNA vaccine [9, 10]. Due to the sharp increase in the delta variant (Pango-lineage
- 63 [11] B.1.617.2) in Germany, the STIKO has revised its recommendations once more. Since July 1st 2021,
- 64 all AZD1222 first vaccinated persons have been recommended to complete the second vaccination
- 65 with an mRNA vaccine [12]. Animal experiments indicated very good humoral and cellular immunity
- after heterologous vaccination [13, 14]. There is, however, so far only little knowledge on the benefit
- 67 of the heterologous vaccination scheme in humans. First results indicated a higher prevalence of short-
- 68 lived side effects following the heterologous boost dose compared to the homologous counterpart
- 69 [15]. Only a few and mostly preliminary results have so far been published for the immunogenicity of
- 70 the AZD1222 / mRNA vaccine regimen [16-19].
- 71 In this study, we compare the SARS-CoV-2 specific immunoglobulin G (IgG) response after
- 72 heterologous immunisation with that elicited by homologous vaccination schedules. We also focus on
- 73 the developing anti-SARS-CoV-2 IgG avidity as a parameter for IgG maturity and binding strength.

- 74 Finally, we use various methods to investigate the development of VNA. Therefore, humoral immunity
- 75 induced by vaccines is being extensively studied. We believe that the results obtained in this study will
- 76 help to better understand the effects and possibly benefits of a heterologous vaccination regimen.

Methods

77

96

97

98 99

100

101

102

103

104

105

106

107

108

109

110

78 The anti-S and anti-RBD IgG response after heterologous immunisation with a SARS-CoV-2 vector 79 vaccine as prime and an mRNA vaccine as boost was compared to that after homologous vaccination with vector or mRNA vaccines. This setting also includes monitoring of IgG avidity and of virus-80 neutralizing capacities. Forty-seven female and twelve male vaccinees with a median age of 31 years 81 82 (age span 18 - 61 years) were recruited for this study and gave their informed consent. Forty-two of 83 them received a heterologous immunisation scheme (N=41, AZD1222/BNT162b2; N=1, 84 AZD1222/mRNA-1273), while nine and eight vaccinees received a homologous scheme of the vector vaccine AZD1222 or the mRNA vaccine BNT162b2, respectively. The first blood sample was taken at a 85 86 median of 68 days after initial vaccination and the second sample was taken at a median of 15 days 87 after the second immunisation. For several individuals no serum was available before or after the 88 booster vaccination (Table 1). The ethics committee of the medical faculty of the Christian-Albrechts-89 Universität zu Kiel (Kiel, Germany) approved the study design (D467/20, 16.04.2020, amendment 90 02.02.2021). We examined the early humoral immune response (other samples obtained a few days to weeks after the initial immunisation with AZD1222) of most of the subjects in a previous study. In 91 92 addition, sera obtained from three vaccinees after the initial immunisation with BNT162b2 (N=2) and 93 AZD1222 (N=1) have already been tested in frame of the previous study [20]. In this respect, we consider it justified to include these individuals (and few sera) in the present report and to 94 95 demonstrate the results before and after the booster vaccination.

Anti-SARS-CoV-2 specific IgG immunoassays

The sera were tested with the SERION ELISA agile SARS-COV-2 IgG assay (S-protein as antigen; Institut Virion\Serion GmbH, Würzburg, Germany) and the Abbott SARS-CoV-2 IgG II Quant assay (RBD as antigen; Abbott, Wiesbaden, Germany) as described previously [20]. In addition, the LIAISON® SARS-CoV-2 Trimeric S IgG assay was included as a further assay on a LIAISON® XL system (both Diasorin S.p.A, Saluggia, Italy). According to the manufacturer, this quantitative chemiluminescence immunoassay detects IgG directed against the trimeric S-protein and has an excellent clinical sensitivity and specificity of 98.7% and 99.5%, respectively. The high diagnostic value of this test has also been demonstrated in a recent seroprevalence study [21]. The results of the three IgG assays were given in Binding Antibody Units (BAU) per milliliter (BAU / ml), using the manufacturer's conversion factors, which were based on measurements of the WHO International Standard Anti-SARS-CoV-2 Immunoglobulin (NIBSC code 20-136) [22]. As in our previous studies, we generally rate borderline test results as positive [23, 20].

Anti-SARS-CoV-2 IgG immunoblots including measurement of IgG avidities

All sera were tested with and without avidity reagent in the recomLine SARS-CoV-2 IgG assay (Mikrogen 111 GmbH, Neuried, Germany) as reported previously [23, 20]. The strength of SARS-CoV-2 antigen binding 112 against the S1-and RBD-subunits of the S-protein and against the nucleoprotein (NP, if detectable) was 113 114 assigned to the categories low (= 1), intermediate (= 2), and high (= 3) [20]. Measurement of SARS-CoV-2-neutralising antibodies with two different assays 115 The sera were examined for their virus-neutralising capacities. First, a surrogate assay was used (TECO® 116 SARS-CoV-2 Neutralisation Antibody ELISA; TECOmedical AG, Sissach, Switzerland). In this competetive 117 assay, the human angiotensin-converting enzyme 2 (ACE-2) was attached to the solid phase while 118 peroxidase-conjugated RBD was present in the liquid phase. If the human serum contained RBD-119 120 specific antibodies, binding of RBD to ACE-2 was prevented. Hence, after washing steps the color 121 reaction turned out to be weaker compared to a RBD-antibody-free serum sample. According to the 122 manufacturer, it is assumed from an inhibition of 20% that VNA are present. 123 Second, dilutions of each serum were tested in triplicate in a laboratory-developed Vero cell-based 124 neutralisation assay (cVNT). This 96-well format cVNT uses an own B.1.1.7 strain from January 2021 as 125 antigen. A dilution >1:10 was considered likely protective [23, 20]. 126 Data evaluation and statistical calculations 127 Data were statistically analysed by help of the GraphPad Prism version 9.1.2 software (GraphPad 128 Software, San Diego, CA, USA). We generally used the Kruskal-Wallis test, an adjusted, non-paired and non-parametric test. The significance level was defined as 0.05. Furthermore, we calculated the 129 130 Pearson correlation coefficient r to demonstrate the linear correlation between separate data sets. 131 We used simple logistic regression to determine the probability of detecting VNA with our cVNT as a function of sVNT results. 132 133 Results Composition of the study groups 134 135 This study included 59 individuals. Nine and eight of them received a homologous vaccination with 136 AZD1222 or BNT162b2, respectively, while 42 received a heterologous vaccination. The composition 137 of the study groups including median age, age-span, gender and time span of blood sampling is presented in Table 1. 138 139 140 141 142 143 144

Table 1. Individuals included in this study

Study groups	Number of individuals after 1 st /2 nd vaccination	Median age in years	• .	Gender (female/male)	Time span from 1st/2nd vaccination to 1st/2nd serum sampling in days
Heterologous vaccination scheme					
AZD1222/BNT162b2	30/41	27	18-56	33/8	69/16
AZD1222/mRNA-1273	1/1	45	45-45	1/0	64/14
Homologous vaccination scheme					
AZD1222	8/9	41	23-61	6/3	34/14
BNT162b2	8/8	35	23-51	7/1	34/14

After the first immunisation, all individuals who received an mRNA vaccine developed anti-(trimeric)-S and anti-RBD-IgG. The vaccinees who received the AZD1222 had a prevalence of 55.3 % (anti-S IgG), 76.3 % (anti-trimeric S IgG) and 94.7 % (anti-RBD IgG), respectively. After administration of the second dose, the IgG prevalence reached 100% in all groups. The mean anti-SARS-CoV-2 IgG titres varied between 39.9 BAU/ml (anti-S IgG; first vaccination in the AZD1222/mRNA group) to 6584 BAU/ml (anti-trimeric S IgG; second vaccination in the BNT162b2/BNT162b2 group). After the second vaccine dose, an increase in mean anti-SARS-CoV-2 titres was observed in all three study groups and in all assays. Compared to the mean anti-SARS-CoV-2 IgG titres after the vector vaccine AZD1222 was administered twice, the corresponding titres were 7 to 10 times higher after a heterologous vaccination and even 10 to 15 times higher according to the homologous BNT162b2 vaccination scheme (Figure 1).




Figure 1: Anti-SARS-CoV-2 immunoglobulin G response after first (1; empty circles) and second (2; filled circles) immunisation with the vector vaccine AZD1222 or the messenger ribonucleic acid (mRNA)-based vaccines BNT162b2 or mRNA-1273. The cut-offs for positivity (including borderline results) of anti-trimeric spike (S) IgG assay (A), of the anti-S IgG assay (B), and of the anti-RBD IgG assay (C), respectively, are marked by dashed lines. Ns: non-significant; *: p < 0.05; **: p < 0.01; ****: p < 0.001 (adjusted non-paired and non-parametric test; Kruskal-Wallis test).

Next, we examined the development of anti SARS-CoV-2 IgG avidity in an immunoblot. After the first vaccination, the mean avidity index was in the low to intermediate range. In contrast, high avidities were consistently observed after administration of the second vaccine dose (Figure 2). None of the vaccinees showed an IgG reactivity against the NP in the immunoblot (data not shown).

170

171

172

173

174

175

176

177

178

179180

181

182

183

184

185

186187

188

189

190




Figure 2: Development of anti-SARS-CoV-2 immunoglobulin G avidities after first (1; empty circles) and second (2; filled circles) immunisation with the vector vaccine AZD1222 or the messenger ribonucleic acid (mRNA)-based vaccines BNT162b2 or mRNA-1273. The measured IgG avidities were assigned to the three categories low (1), intermediate (2) and high (3). Ns: non-significant; *: p < 0.05; **: p < 0.01; ****: p < 0.001 (adjusted non-paired and non-parametric test; Kruskal-Wallis test).

The virus-neutralising properties of the sera were examined with two different assays. A so-called surrogate neutralisation test was used to investigate the extent to which the anti-RBD antibodies that may be present in the serum are able to prevent the binding of this S-protein subunit to the human receptor ACE2. In addition, a laboratory-developed virus-neutralisation test was used, which is based on a B.1.1.7 strain as the antigen. While the majority of the sera in the sVNT were already to be regarded as neutralizing after the first vaccination, these samples did not yet show any corresponding properties in the cVNT. With both methods, however, an increase in the level of VNA could be detected after a second vaccination. There were also marked differences between the three vaccination groups, both in the degree of inhibition (sVNT) and in the level of VNA titres (cVNT). Vaccinees who had received the vector vaccine only had 13- and 11-fold lower geometric mean VNA titres (1:47) compared to individuals immunised heterologously with AZD1222 / mRNA (1:608) or homologously with BNT162b2 (1:538), respectively. However, the mean % inhibition of sVNT reached about the same level in all three groups (Figure 3). Even though the quantitative results correlate with a Pearson correlation coefficient r of 0.84 well in both tests, it is noticeable that especially non-neutralising sera (≤1:10) are overestimated in the sVNT. This is evidenced by the fact that the cut-off set by the manufacturer is only associated with a 4 % probability of detecting VNA in our cVNT (Figure 4).




Figure 3: Development of SARS-CoV-2 neutralising antibodies (VNA) after first (1; empty circles) and second (2; filled circles) immunisation with the vector vaccine AZD1222 or the messenger ribonucleic acid (mRNA)-based vaccines BNT162b2 or mRNA-1273. A surrogate neutralisation assay (A) and a Vero-cell based virus-neutralisation test (B) using a B.1.1.7 strain were used to measure the VNAs. The assay cut-offs are indicated by dashed lines. Ns: non-significant; *: p < 0.05; **: p < 0.01; ****: p < 0.0001 (adjusted non-paired and non-parametric test; Kruskal-Wallis test).




Figure 4: Correlation of the surrogate neutralisation test (sVNT) results with results obtained by the laboratory developed Vero-cell based virus-neutralisation test (cVNT) using a B.1.1.7 strain as antigen (A). The Pearson correlation coefficient r of log(reciprocal titre) was calculated with 0.84; empty circles; first vaccination; filled circles: second vaccination; red: heterologous vaccination with AZD1222/mRNA; green: homologous vaccination with AZD1222; blue: homologous vaccination with BNT162b2. Probability of detecting virus-neutralising antibodies (VNA) with the in-house cVNT at a given % inhibition of sVNT calculated by logistic regression (B); e.g. at 20% inhibition (black dashed line), 63% inhibition (red dashed line), and at 85% inhibition of sVNT (red dashed line), the probabilities of detecting VNA with cVNT are 4% (95%Cl 1%-16%), 50 % (95%Cl 34%-66%) and 83% (95%Cl 70%-91%), respectively.

Discussion

Due to the rare but serious side effects after administration of the vector vaccine, in spring 2021 the STIKO recommended that people under the age of 60 should complete vaccinations that had already been started with a vector vaccine with an mRNA vaccine [9, 10]. This recommendation was extended on July 1st, 2021 to all who had already received a primary vaccination with AZD1222 [12]. In the first quarter of this year, however, only a few animal experimental data were available on the immunological outcome of the proposed heterologous vaccination scheme [13, 14]. Several preprints have now appeared on the immunogenicity of the heterologous vaccination scheme in humans [16-19].

We took this general knowledge gap as an opportunity to compare the development of the humoral immune response after homologous and heterologous vaccination.

After the first vaccination, the majority of vaccinees developed anti-trimeric-S, -S, and -RBD IgG antibodies, respectively. However, their titres varied between the three study groups. The results are in line with our previous study [20]. It is evident that the anti-SARS-CoV-2 IgG titres are not comparable between the three assays either. This is probably due to the different antigen preparations. In this respect, from our point of view, titre comparisons are only possible if they have been measured with the same assay.

The second vaccination resulted in higher titres in all three groups. It was noticeable that significantly higher anti-SARS-CoV-2 IgG titres were detected after a second vaccination with an mRNA vaccine than after the vector vaccine AZD1222 was administered again. The increase in anti-S and anti-RBD IgG titres after a second vaccination with an mRNA vaccine confirms our previous study. Due to the recommended vaccination interval of 10 to 12 weeks, we did not yet have any data on the development of the SARS-CoV-2-specific IgG antibodies after the second administration of a vector vaccine [20]. The absence of NP-specific IgG antibodies in all vaccinated persons can be interpreted as a hint that they have not had a SARS-CoV-2 infection and were therefore to be regarded as immunologically naive before the vaccination [20]. It is known that vaccinations lead to particularly high anti-SARS-CoV-2 IgG titres in convalescents [24]. For these individuals, the recommendation is that they should receive a vaccine dose about six months after they have been infected [10].

After the first vaccination nearly all vaccinees exhibited only low to intermediate avid anti-SARS-CoV-2 IgG, while after the second vaccine dose IgG of high avidity appeared in all cases. In line with this, VNA > 1:10 against the prevalent VOC B.1.1.7 strain were observed after second vaccination. The results confirm our previous study [20]. Marked differences in the level of VNA titres were observed between individuals re-vaccinated with an mRNA vaccine and those re-vaccinated with a vector vaccine which is in accordance to previous animal experiments [13]. Basically, the sVNT also showed the titre increase and evaluated all sera as virus-neutralizing after the second vaccination. However, it is again noticeable that sera that are not or only weakly virus-neutralising in the in-house cVNT are already evaluated as neutralising in the sVNT. This result underscores our previous suggestion to raise the cut-off of the sVNT [20]. Compared to the admittedly very conservative in-house cVNT, a cut-off of

244 over 80% would be desirable. Due to the lack of standardisation of the widespread cVNTs for the 245 detection of VNA against SARS-CoV-2, this recommendation only applies to our laboratory and cannot 246 be generalised. 247 The data presented by us on the humoral immune response after heterologous SARS-CoV-2 248 vaccination are consistent with the few available clinical studies [16, 18, 17, 19]. A recent preprint reports significant higher anti-S-antibody titres in a group of 26 individuals who first received an 249 250 AZD1222 vaccination followed by re-vaccination with BNT162b2 compared to 14 individuals that were 251 vaccinated twice with BNT162b2. These results were obtained with a total antibody assay which does 252 not discriminate between IgG and acute phase immunoglobulin M. Nearly four-fold higher virusneutralising titres were observed in the AZD1222/BNT162b2 group using a chimeric vesicular 253 254 stomatitis virus carrying the S-protein of SARS-CoV-2 VOC B.1.1.7 as antigen. However, data after 255 homologous vaccination with the vector vaccine are missing in this study [16]. We also observe 256 differences in the titre level of the VNA in the cVNT. However, these are not to be regarded as 257 significant in every case. 258 In another preprint [18], differences in the anti-S IgG and VNA titres were not observed after 259 heterologous vaccination (AZD1222/mRNA) or after homologous vaccination with an mRNA vaccine. 260 In contrast, both parameters were significantly lower after homologous vaccination with the vector 261 vaccine [18]. These results are in agreement with our data even if only one IgG assay and one sVNT 262 were used by this research group. 263 The results of a previously non-peer reviewed single-blind randomised British study, in which the four 264 possible vaccine combinations of AZD1222 and BNT162b2 were compared with one another, are very 265 interesting and promising. These researchers report about 9-fold higher mean anti-S IgG titres in 266 heterologous AZD1222/BNT162b2 vaccinees compared to individuals immunized twice with AZD1222 267 [19] which is largely in accordance to our results. 268 Only one preprint investigates the development of IgG avidity after heterologous SARS-CoV-2 269 vaccination in humans [17]. Therein the immune response after heterologous vaccination was 270 compared with that after homologous vaccination with an mRNA vaccine. However, results obtained 271 after homologous vaccination with a vector vaccine are missing. The authors demonstrate comparable 272 IgG responses after the booster vaccination and an increase in VNA (determined by sVNT) as wells as 273 of IgG avidity [17], which is in line to our data and to results of animal experiments [13]. 274 It is not yet sufficiently clear why homologous vaccination with the AZD1222 vector vaccine leads to 275 lower anti-SARS-CoV-2 IgG and VNA titres. A possible explanation could be the immune response to the adenovirus vector backbone (so called "antivector immunity" [3]). 276 277 The work presented by us contributes to a better understanding of the humoral immunogenicity of the heterologous SARS-CoV-2 vaccination regimen. With various assays we monitored the 278 279 development of anti S-specific IgG antibodies and make statements about their binding-strength as an 280 expression of maturity. In addition, with a commercial and an in-house test, we showed that VNA can

be detected after the second vaccination. Important limitations of our report are (i) the heterogeneity

of the study groups, (ii) the small group size of individuals who received a homologous vaccination scheme, (iii) the subjects, who are predominantly in younger to middle adulthood, (iv) the lack of information on the durability of the detected antibodies, and (v) the missing consideration of cellular and innate immunity after immunisation. Therefore, among other things, no statements can be made from our data about the need for further booster vaccinations. In addition, no better protection against SARS-CoV-2 infections can be derived from the level of the antibody titre *per se*.

In summary, the combination of a first vaccination with a vector vaccine followed by a second administration of an mRNA vaccine leads to a strong humoral immune response, comparable to that achieved after two vaccinations with an mRNA vaccine. Regardless of the vaccination schedule, all individuals develop highly avid anti-SARS-CoV-2 IgGs and VNA shortly after the second vaccination.

295

296

297

298

299

300

301302

303

304

305306

307

308 309

310

311

312

313

Availability of data: The data presented in this study are available on request from the corresponding author. Ethics approval and consent to participate: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of the medical faculty of the Christian-Albrechts-Universität zu Kiel, Kiel, Germany (D467/20, 16.04.2020; amendment 02.02.2021). Informed consent was obtained from all subjects involved in the study. Consent for publication: Not applicable. Competing interests: The companies Diasorin GmbH, Mikrogen GmbH and Tecomedical GmbH supported this study by providing free or discounted kits. None of the three companies had any influence on the testing and the interpretation of the results. The authors declare that they have no competing interests. Author Contributions: AK, FN, and RR had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: AK. Acquisition, analysis, or interpretation of the data: all authors. Drafting of the manuscript: AK, HF and RR. Critical revision of the manuscript for important intellectual content: all authors. All authors have read and agreed to the published version of the manuscript. **Funding:** This research received no external funding. **Acknowledgments:** The authors would like to thank all subjects for participating in the study.

References

314

- 1. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol.
- 317 2021;19(3):141-54. doi:10.1038/s41579-020-00459-7.
- 318 2. Klasse PJ, Nixon DF, Moore JP. Immunogenicity of clinically relevant SARS-CoV-2 vaccines in
- 319 nonhuman primates and humans. Sci Adv. 2021;7(12). doi:10.1126/sciadv.abe8065.
- 320 3. Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced
- 321 protection against COVID-19 in humans. Nature Reviews Immunology. 2021. doi:10.1038/s41577-021-
- 322 00578-z.
- 323 4. Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586(7830):516-27.
- 324 doi:10.1038/s41586-020-2798-3.
- 325 5. Cines DB, Bussel JB. SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia. N Engl J
- 326 Med. 2021;384(23):2254-6. doi:10.1056/NEJMe2106315.
- 327 6. Kyriakidis NC, Lopez-Cortes A, Gonzalez EV, Grimaldos AB, Prado EO. SARS-CoV-2 vaccines strategies:
- 328 a comprehensive review of phase 3 candidates. NPJ Vaccines. 2021;6(1):28. doi:10.1038/s41541-021-
- 329 00292-w.
- 330 7. Creech CB, Walker SC, Samuels RJ. SARS-CoV-2 Vaccines. JAMA. 2021;325(13):1318-20.
- 331 doi:10.1001/jama.2021.3199.
- 8. EU. Safe COVID-19 vaccines for Europeans. 2021. https://ec.europa.eu/info/live-work-travel-
- 333 <u>eu/coronavirus-response/safe-covid-19-vaccines-europeans en</u>. Accessed 12 May 2021.
- 334 9. STIKO. Stellungnahme der Ständigen Impfkommission zum Zeitpunkt der Gabe eines mRNA-
- 335 Impfstoffs nach Erstimpfung mit AstraZeneca Vaccine (Vaxzevria) bei <60-Jährigen. 2021.
- 336 https://www.rki.de/DE/Content/Kommissionen/STIKO/Empfehlungen/Stellungnahme-
- 337 <u>Impfabstand.html</u>. Accessed 12 May 2021.
- 338 10. RKI. Mitteilung der Ständigen Impfkommission beim Robert Koch-Institut Beschluss der STIKO zur
- 7. Aktualisierung der COVID-19-Impfempfehlung und die dazugehörige wissenschaftliche Begründung.
- 340 Epidemiologisches Bulletin. 2021;25:3-13.
- 341 11. Rambaut A, Holmes EC, O'Toole Á, Hill V, McCrone JT, Ruis C et al. A dynamic nomenclature
- 342 proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nature Microbiology.
- 343 2020;5(11):1403-7. doi:10.1038/s41564-020-0770-5.
- 344 12. STIKO. Mitteilung der STIKO zur COVID-19-Impfung: Impfabstand und heterologes Impfschema
- 345 nach Erstimpfung mit Vaxzevria (1.7.2021). 2021.
- 346 https://www.rki.de/DE/Content/Kommissionen/STIKO/Empfehlungen/PM 2021-07-01.html.
- 347 Accessed 2 July 2021.
- 348 13. Spencer AJ, McKay PF, Belij-Rammerstorfer S, Ulaszewska M, Bissett CD, Hu K et al. Heterologous
- 349 vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune
- 350 responses in mice. Nature Communications. 2021;12(1):2893. doi:10.1038/s41467-021-23173-1.
- 351 14. He Q, Mao Q, An C, Zhang J, Gao F, Bian L et al. Heterologous prime-boost: breaking the protective
- 352 immune response bottleneck of COVID-19 vaccine candidates. Emerging Microbes & Infections.
- 353 2021;10(1):629-37. doi:10.1080/22221751.2021.1902245.

- 354 15. Shaw RH, Stuart A, Greenland M, Liu X, Van-Tam JSN, Snape MD et al. Heterologous prime-boost
- 355 COVID-19 vaccination: initial reactogenicity data. Lancet. 2021;397(10289):2043-6.
- 356 doi:10.1016/S0140-6736(21)01115-6.
- 357 16. Groß R, Zanoni M, Seidel A, Conzelmann C, Gilg A, Krnavek D et al. Heterologous ChAdOx1 nCoV-
- 358 19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell
- 359 reactivity. medRxiv. 2021:2021.05.30.21257971. doi:10.1101/2021.05.30.21257971.
- 360 17. Hillus D, Schwarz T, Tober-Lau P, Hastor H, Thibeault C, Kasper S et al. Safety, reactogenicity, and
- 361 immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1-nCoV19
- 362 and BNT162b2: a prospective cohort study. medRxiv. 2021:2021.05.19.21257334.
- 363 doi:10.1101/2021.05.19.21257334.
- 18. Schmidt T, Klemis V, Schub D, Mihm J, Hielscher F, Marx S et al. Immunogenicity and reactogenicity
- 365 of a heterologous COVID-19 prime-boost vaccination compared with homologous vaccine regimens.
- 366 medRxiv. 2021:2021.06.13.21258859. doi:10.1101/2021.06.13.21258859.
- 367 19. Liu X, Shaw RH, Stuart ASV, Greenland M, Dinesh T, Provstgaard-Morys S et al. Safety and
- 368 Immunogenicity Report from the Com-COV Study a Single-Blind Randomised Non-Inferiority Trial
- 369 Comparing Heterologous And Homologous Prime-Boost Schedules with An Adenoviral Vectored and
- 370 mRNA COVID-19 Vaccine. SSRN. 2021. doi: http://dx.doi.org/10.2139/ssrn.3874014
- 371 20. Neumann F, Rose R, Römpke J, Grobe O, Lorentz T, Fickenscher H et al. Development of SARS-CoV-
- 2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination.
- 373 Vaccines. 2021;9(7):700.
- 374 21. Bonelli F, Blocki FA, Bunnell T, Chu E, O ADL, Grenache DG et al. Evaluation of the automated
- 375 LIAISON® SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies. Clinical Chemistry
- 376 and Laboratory Medicine (CCLM). 2021;59(8):1463-7. doi:doi:10.1515/cclm-2021-0023.
- 377 22. Kristiansen PA, Page M, Bernasconi V, Mattiuzzo G, Dull P, Makar K et al. WHO International
- 378 Standard for anti-SARS-CoV-2 immunoglobulin. Lancet. 2021;397(10282):1347-8. doi:10.1016/S0140-
- 379 6736(21)00527-4.

- 380 23. Strömer A, Rose R, Grobe O, Neumann F, Fickenscher H, Lorentz T et al. Kinetics of Nucleo- and
- 381 Spike Protein-Specific Immunoglobulin G and of Virus-Neutralizing Antibodies after SARS-CoV-2
- 382 Infection. Microorganisms. 2020;8(10). doi:10.3390/microorganisms8101572.
- 383 24. Frieman M, Harris AD, Herati RS, Krammer F, Mantovani A, Rescigno M et al. SARS-CoV-2 vaccines
- 384 for all but a single dose for COVID-19 survivors. EBioMedicine. 2021;68.
- 385 doi:10.1016/j.ebiom.2021.103401.